TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial

Antzeko izenburuak

• Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms
  nork: Constantine, Ginger D., et al.
  Argitaratua: (2019)
• SAT-238 Predictors Of Vaginal/Uterine Bleeding With Oral TX-001HR (Estradiol and Progesterone) Capsules Taken For Menopausal Vasomotor Symptoms
  nork: Constantine, Ginger, et al.
  Argitaratua: (2019)
• 17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial
  nork: Kaunitz, Andrew M., et al.
  Argitaratua: (2020)
• Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules)
  nork: Lobo, Rogerio A., et al.
  Argitaratua: (2019)
• Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms
  nork: Simon, James A., et al.
  Argitaratua: (2019)